CompScripts-Vet

May this Eid bring happiness to your heart and your family. Eid-ul-Fitr Mubarak! Wishing you a very Happy Eid Mubarak. Cherish every moment of this beautiful festival and know that all your dreams will come true soon.

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer

With 9 new poly adenosine diphosphate-ribose polymerase (PARP) inhibitor drugs approved for ovarian cancer over the past 6 years, increasing amounts of data are finding that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

https://ryze.ly/c181abe5

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

https://ryze.ly/cb75eb02

Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.